ReviewClinical microbiology reviews2015
Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.
Review in Clinical microbiology reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06719219 (A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine), which is not on this map. Cited by 2,395 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine (LTB-SA7) in Healthy Adults.
Who cites it
2,395 citing papers in PubMed, 3 syntheses or guidelines pooled it, 4,961 citations in OpenAlex.
- The Prevalence of Methicillin-resistant Staphylococcus aureus in Clinical Settings of Pakistan: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- Prevalence of healthcare-associated infections in developing and developed countries: a systematic review.BMC infectious diseases · 2026Pooled it
- Prevalence of Streptococcus pneumoniae and Staphylococcus aureus co-colonization in healthy children under five years: a systematic review.BMC pediatrics · 2026Pooled it
- Preclinical and clinical evaluation of vancomycin plus delpazolid combination therapy for MRSA bacteremia: a multicenter, double-blinded, randomized, parallel design, phase IIa clinical trial.Microbiology spectrum · 2026Trial
- Copper-coated carbon nanotube surfaces for inhibiting biofilm formation byCell surface (Amsterdam, Netherlands) · 2026Review
- Microfluidic-assembled curcumin ionizable lipid nanoparticles enhance aqueous delivery and antibiofilm activity againstInternational journal of pharmaceutics: X · 2026Article
- Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting.Annals of medicine · 2026Review
- Phenotypic resistance to life-saving antimicrobials in Gram-positive bacteria isolated from wild birds in Northern Italy: a One Health surveillance perspective.One health (Amsterdam, Netherlands) · 2026Article
- Article
- Auranofin potentiates linezolid activity against MRSA by disrupting redox homeostasis and inhibiting SarA-mediated virulence and biofilm.Virulence · 2026Article
- Epidemiology of adult deceased solid organ donors with positive blood cultures in the USA: a retrospective registry-based study.Lancet regional health. Americas · 2026Article
- Article
- Selective PET imaging of bacterial infection using a glycosylatedNature biomedical engineering · 2026Article
- Microbial Contamination of Radiology Equipment: A Descriptive Study in Ghana.Health science reports · 2026Article
- Single-Cell Membrane-Permeabilization Kinetics Reveal Species-Specific Responses to Antimicrobial Photodynamic Treatment.ACS omega · 2026Article
- Microbiome Profiling Reveals Prognostic Heterogeneity inmedRxiv : the preprint server for health sciences · 2026Article
- Cefazolin Versus Antistaphylococcal Penicillins in Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Review
- Effects of Sub-Inhibitory Rifampicin, Minocycline, and Dalbavancin on Early Biofilm Formation and Transcriptional Responses inMicroorganisms · 2026Article
- InJournal of bacteriology · 2026Article
- Loss of the ApJournal of bacteriology · 2026Article
2,335 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections. It is a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections. This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of each of these clinical entities. The past 2 decades have witnessed two clear shifts in the epidemiology of S. aureus infections: first, a growing number of health care-associated infections, particularly seen in infective endocarditis and prosthetic device infections, and second, an epidemic of community-associated skin and soft tissue infections driven by strains with certain virulence factors and resistance to β-lactam antibiotics. In reviewing the literature to support management strategies for these clinical manifestations, we also highlight the paucity of high-quality evidence for many key clinical questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.